Advertisement

Predictive Biomarkers and Targeted Therapies in Breast Cancer

  • Sunil Badve
Chapter

Abstract

Breast cancer is the most common cancer in women and accounts for more than 250,000 cases in the USA alone. Although a poster child for predictive markers and targeted therapies, progress in treatment for this cancer has been slow. This is particularly true for new predictive biomarkers, and the number of routinely assessed predictive markers is restricted to estrogen, progesterone, and human epidermal growth factor receptors. Proliferation plays an important role in prognostication of ER+ tumors; however, its role in prediction is uncertain. Cell cycle (CDK4/CDK6) inhibitors such as palbociclib/ribociclib have been demonstrated to have a place in the management of ER+ cancers. HER2 positivity predicts for response to a number of anti-HER2 targeted therapies. Patients with BRCA1/BRCA2 mutations respond well to PARP inhibitor (PARPi; e.g., olaparib) therapy. The role of PARPi in other types of breast cancer remains to be established. The high prevalence of breast cancer and failure of standard of care therapies have resulted in intense focus on developing novel therapies including targeted therapies. A number of agents have been tried either in combination with endocrine therapy and/ or chemotherapy for the treatment of metastatic cancer.

Keywords

Breast cancer Predictive markers ER TNBC HER2 therapy 

References

  1. 1.
    Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.CrossRefPubMedGoogle Scholar
  2. 2.
    Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 2012;486(7403):346–52.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415–21.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750–67.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature. 2012;486(7403):353–60.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Singh JC, Jhaveri K, Esteva FJ. HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. Br J Cancer. 2014;111(10):1888–98.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Andre F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, et al. Molecular alterations and everolimus efficacy in human epidermal growth factor receptor 2-overexpressing metastatic breast cancers: combined exploratory biomarker analysis from BOLERO-1 and BOLERO-3. J Clin Oncol. 2016;34(18):2115–24.CrossRefPubMedGoogle Scholar
  8. 8.
    Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Masuda H, Baggerly KA, Wang Y, Zhang Y, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013;19(19):5533–40.CrossRefPubMedGoogle Scholar
  10. 10.
    Kalimutho M, Parsons K, Mittal D, Lopez JA, Srihari S, Khanna KK. Targeted therapies for triple-negative breast cancer: combating a stubborn disease. Trends Pharmacol Sci. 2015;36(12):822–46.CrossRefPubMedGoogle Scholar
  11. 11.
    Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32(27):2959–66.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28(16):2784–95.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013.CrossRefPubMedGoogle Scholar
  15. 15.
    Fehrenbacher L, Cecchini RS, Geyer CE, Rastogi P, Costantino JP, Atkins JN, et al. NSABP B-47 (NRG oncology): phase III randomized trial comparing adjuvant chemotherapy with adriamycin (A) and cyclophosphamide (C) -> weekly paclitaxel (WP), or docetaxel (T) and C with or without a year of trastuzumab (H) in women with node-positive or high-risk node-negative invasive breast cancer (IBC) expressing HER2 staining intensity of IHC 1+or 2+with negative FISH (HER2-Low IBC). Cancer Res. 2018;78(4).CrossRefGoogle Scholar
  16. 16.
    Esposito A, Criscitiello C, Curigliano G. Highlights from the 14(th) St Gallen international breast cancer conference 2015 in Vienna: dealing with classification, prognostication, and prediction refinement to personalize the treatment of patients with early breast cancer. Ecancermedicalscience. 2015;9:518.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Leung SCY, Nielsen TO, Zabaglo L, Arun I, Badve SS, Bane AL, et al. Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2:16014.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Burgess A, Chia KM, Haupt S, Thomas D, Haupt Y, Lim E. Clinical overview of MDM2/X-targeted therapies. Front Oncol. 2016;6:7.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, Neciosup SP, et al. Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol. 2015;16(7):816–29.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of Pathology and Lab MedicineIndiana University School of MedicineIndianapolisUSA

Personalised recommendations